IC9 CAR.19 is under clinical development by Bellicum Pharmaceuticals and currently in Phase I for Burkitt Lymphoma. According to GlobalData, Phase I drugs for Burkitt Lymphoma have a 68% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how IC9 CAR.19’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IC9 CAR.19 overview
iC9 CAR.19 is under development for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, nodal marginal zone B-cell lymphoma, splenic marginal zone B -cell lymphoma, extranodal marginal zone B-cell lymphoma (mucosa-associated lymphoid tissue or malt-lymphoma), primary mediastinal B-cell lymphoma, mantle cell lymphoma, primary CNS lymphoma, Waldenstrom macroglobulinemia and chronic lymphocytic leukemia (CLL/SLL). It is administered through intravenous route. It comprises chimeric antigen receptor (CAR) T cells which acts by targeting CD19 protein expressed on cancer cells. AP1903 is administered to activate the iC9-CAR19 safety switch by inducing caspase9 in case of cytokine release syndrome.
Bellicum Pharmaceuticals overview
Bellicum Pharmaceuticals (Bellicum) is a clinical-stage biopharmaceutical company. It primarily focuses on the development and commercialization of novel cellular immunotherapies for various forms of cancer. The company’s product candidates include BPX-601 and BPX-603, that are designed to be more efficacious CAR-T cell products capable of overriding key immune inhibitory mechanisms. Bellicum’s GoCAR technology builts a enhance effector cell proliferation and functional persistence and is designed to enlist wider immune cell engagement to target resistant tumor cells. Its therapies are primarily targeted towards cancer patients, aiming to provide more effective treatment options. The company operates in the US. Bellicum is headquartered in Houston, Texas, the US.
For a complete picture of IC9 CAR.19’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
